The high efficacy claims of these companies are, however,  based on a very small number of people analysed to see interim efficacy. In the case of Pfizer and BioNTech, 170 participants (highest amongst the three) were analysed, followed by Moderna (95) and Russia's Gamalaya that analysed the efficacy of Sputnik V vaccine on just 20 participants suffering from COVID-19.